Show simple item record

dc.contributor.authorHamadani, M.
dc.contributor.authorKanate, A.S.
dc.contributor.authorDiGilio, A.
dc.date.accessioned2019-07-15T16:12:13Z
dc.date.available2019-07-15T16:12:13Z
dc.date.issued2017
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85013473580&doi=10.1016%2fj.bbmt.2017.01.082&partnerID=40&md5=ffedc4af5fae45f7941dedf45692d114
dc.identifier.urihttp://hdl.handle.net/10713/9946
dc.description.abstractAggressive NK cell leukemia (ANKL) is an exceedingly rare form of leukemia and carries a poor prognosis, with a median survival of only 2 months. Using the Center for International Blood and Marrow Transplant Research database, we evaluated outcomes of allogeneic hematopoietic cell transplantation (alloHCT) in patients with ANKL. Twenty-one patients with a centrally confirmed diagnosis of ANKL were included. Median patient age was 42 years and 15 patients (71%) were Caucasian. Fourteen patients (67%) were in complete remission (CR) at the time of alloHCT, and 5 patients had active disease. Median follow-up of survivors was 25 months (range, 12 to 116). The 2-year estimates of nonrelapse mortality, relapse/progression, progression-free (PFS), and overall survival (OS) were 21%, 59%, 20%, and 24%, respectively. The 2-year PFS of patients in CR at the time of alloHCT was significantly better than that of patients with active disease at transplantation (30% versus 0%; P?=?.001). The 2-year OS in similar order was 38% versus 0% (P?<?.001). In conclusion, this registry analysis that included majority non-Asian patient population shows that alloHCT can provide durable disease control in a subset of ANKL patients. Achieving CR before transplantation appears to be a prerequisite for successful transplantation outcomes. Copyright 2017 The American Society for Blood and Marrow Transplantationen_US
dc.description.sponsorshipThe CIBMTR is supported by Public Health Service grant/cooperative agreement U24-CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); a grant/cooperative agreement 5U10HL069294 from NHLBI and NCI; a contract HHSH250201200016C with Health Resources and Services Administration (HRSA/DHHS); 2 grants N00014-13-1-0039 and N00014-14-1-0028 from the Office of Naval Research; and grants from various coorporations.en_US
dc.description.urihttps://www.doi.org/10.1016/j.bbmt.2017.01.082en_US
dc.language.isoen_USen_US
dc.publisherElsevier Inc.en_US
dc.relation.ispartofBiology of Blood and Marrow Transplantation
dc.subjectAggressive natural killer cell leukemiaen_US
dc.subjectAllogeneic transplantationen_US
dc.subjectMyeloablativeen_US
dc.subjectReduced-intensity conditioningen_US
dc.titleAllogeneic Hematopoietic Cell Transplantation for Aggressive NK Cell Leukemia. A Center for International Blood and Marrow Transplant Research Analysisen_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.bbmt.2017.01.082
dc.identifier.pmid28161608


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record